Neoleukin Therapeutics (NLTX) News Today → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free NLTX Stock Alerts $33.59 +2.04 (+6.47%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative March 14, 2024 | marketbeat.comNeoleukin Therapeutics (NASDAQ:NLTX) Shares Down 0.8% Neoleukin Therapeutics (NASDAQ:NLTX) Trading Down 0.8%December 20, 2023 | finance.yahoo.comIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 15, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitDecember 4, 2023 | benzinga.comNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesOctober 5, 2023 | markets.businessinsider.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…September 26, 2023 | finanznachrichten.deNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitAugust 18, 2023 | benzinga.comNeoleukin Therapeutics Recent Insider ActivityAugust 18, 2023 | finance.yahoo.comBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUAugust 1, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXJuly 28, 2023 | finance.yahoo.comRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics IncJuly 26, 2023 | benzinga.comMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmJuly 24, 2023 | 247wallst.comBaker Bros. Advisors Now Owns 19.99% of Neoleukin TherapeuticsJuly 19, 2023 | markets.businessinsider.comNeurogene, Neoleukin Announce Planned MergerJuly 18, 2023 | msn.comUniv. of Washington spinout Neoleukin Therapeutics merging with New York City startupJuly 18, 2023 | finanznachrichten.deNeoleukin Therapeutics, Inc.: Neurogene and Neoleukin Announce Definitive Merger AgreementJuly 18, 2023 | benzinga.comNeoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For Neurological DiseasesJuly 18, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQJuly 18, 2023 | msn.comNeoleukin jumps 7% on Neurogene mergerJuly 18, 2023 | marketwatch.comNeoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal >NLTXJuly 18, 2023 | technews.tmcnet.comNLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to ShareholdersJuly 18, 2023 | finance.yahoo.comNeurogene and Neoleukin Announce Definitive Merger AgreementMay 23, 2023 | finance.yahoo.comBiomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)May 9, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Hold Rating on Neoleukin Therapeutics (NLTX)April 7, 2023 | bizjournals.comNeoleukin Therapeutics promotes general counsel to interim CEOMarch 31, 2023 | seekingalpha.comNLTX Neoleukin Therapeutics, Inc.March 21, 2023 | markets.businessinsider.comNeoleukin Therapeutics (NLTX) Receives a Hold from Mizuho SecuritiesMarch 10, 2023 | finance.yahoo.comHere's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn SituationMarch 10, 2023 | bizjournals.comSeattle biotech company CEO steps down amid steep job cutsMarch 9, 2023 | marketwatch.comNeoleukin Therapeutics Shares Climb 29% on 70% Workforce Reduction, Strategic AlternativesMarch 9, 2023 | msn.comShares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or mergerMarch 9, 2023 | finance.yahoo.comNeoleukin Therapeutics Seeks Strategic Alternatives, To Layoff More In Round 2 Within 6 MonthsMarch 9, 2023 | msn.comNeoleukin Therapeutics to cut 70% workforce, CEO steps downMarch 8, 2023 | marketwatch.comNeoleukin Therapeutics Eyes Strategic Alternatives, Will Cut StaffMarch 8, 2023 | markets.businessinsider.comMizuho Securities Keeps Their Hold Rating on Neoleukin Therapeutics (NLTX)March 8, 2023 | finance.yahoo.comNeoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership TransitionDecember 12, 2022 | finance.yahoo.comNeoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual MeetingNovember 16, 2022 | finance.yahoo.comNeoleukin (NLTX) Stops Development of Lead Drug, Stock DownNovember 15, 2022 | markets.businessinsider.comMizuho Securities downgrades Neoleukin Therapeutics (NLTX) to a HoldNovember 15, 2022 | finance.yahoo.comNeoleukin Pauses Development Of NL-201, Cuts 40% Of Employee StrengthNovember 15, 2022 | seekingalpha.comNeoleukin cut to Hold at Stifel on plans to drop lead assetNovember 15, 2022 | markets.businessinsider.com5 Analysts Have This to Say About Neoleukin TherapeuticsNovember 15, 2022 | finance.yahoo.comNeoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate UpdateNovember 14, 2022 | marketbeat.comTrading was temporarily halted for "NLTX" at 04:11 PM with a stated reason of "News pending."November 3, 2022 | finance.yahoo.comNeoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual MeetingOctober 1, 2022 | finance.yahoo.comWe're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn RateAugust 10, 2022 | seekingalpha.comNeoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call TranscriptAugust 10, 2022 | seekingalpha.comNeoleukin Therapeutics, Inc. 2022 Q2 - Results - Earnings Call PresentationAugust 9, 2022 | msn.comRecap: Neoleukin Therapeutics Q2 Earnings Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address “Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher. Click here to claim your free seat ticket now. NLTX Media Mentions By Week NLTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NLTX News Sentiment▼0.000.55▲Average Medical News Sentiment NLTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NLTX Articles This Week▼00▲NLTX Articles Average Week Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Inozyme Pharma News Aquestive Therapeutics News Rani Therapeutics News CorMedix News Ventyx Biosciences News Nature's Sunshine Products News 23andMe News Enanta Pharmaceuticals News Xeris Biopharma News MacroGenics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NLTX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressHow Biden has already won 2024Porter & CompanyBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
